PERSONAL Sign in with your SPIE account to access your personal subscriptions or to use specific features such as save to my library, sign up for alerts, save searches, etc.
Cisplatin (CP) is the primary standard treatment for bladder cancer. Nevertheless, CP has side effects, particularly nephrotoxicity. This limits the treatment of a notable portion of advanced bladder cancer patients with cisplatin. We have developed gold nanoparticles that conjugate CP (CP-AuNPs) for safer delivery to tumors. Here, we investigated the biodistribution of the CP-AuNP conjugates in a mouse model of bladder cancer, to characterize the distinct role of CPAuNP in delivering and releasing CP in tumor and tissues. Effect of the CP-AuNPs on weight and kidney was also investigated. This study can provide insights into the potential safety of CP-AuNP for bladder cancer treatment.
PERSONAL Sign in with your SPIE account to access your personal subscriptions or to use specific features such as save to my library, sign up for alerts, save searches, etc.